基于FIDELITY试验数据的经济学评价:关节镜下半月板部分切除术治疗退行性半月板撕裂与安慰剂手术相比不具有成本效益
基于FIDELITY试验的146例退行性内侧半月板撕裂患者随机接受关节镜下半月板部分切除术(APM,n=70)或安慰剂手术(n=76),2年随访显示APM术后成本并未降低,QALY改善未达统计学显著,在常规支付意愿阈值€35,000/QALY下增量净货币效益为负(€-460)。
要点
- APM组与安慰剂手术组相比,2年随访总成本高€971(95%CI -2013至4017),QALY改善0.015(95%CI -0.011至0.041),均未达统计学显著。
- 在€35,000/QALY的支付意愿阈值下,APM的增量净货币效益为€-460(95%CI -3757至2698)。
- APM仅在支付意愿阈值升至约€65,000/QALY时才出现正的增量净货币效益。
核心结论
- 研究结果进一步支持临床实践指南不推荐对退行性半月板撕裂患者使用APM。
- 鉴于现有证据表明APM相较于非手术治疗或安慰剂手术无获益且不具有成本效益,未来研究不太可能改变这一结论。
研究设计与样本
- 基于FIDELITY试验数据的经济学评价,146例35至65岁、有膝关节症状符合退行性内侧半月板撕裂且根据美国风湿病学会临床标准无膝关节骨关节炎的成人随机接受APM(n=70)或安慰剂手术(n=76)。
- 两组均先行标准诊断性关节镜检查,APM组将撕裂半月板修剪至实性半月板组织,安慰剂手术组仔细模拟APM但不切除半月板组织,手术成本两组相同且未纳入分析。
- 所有患者接受相同的术后护理包括渐进式家庭运动计划,2年随访时安慰剂手术组2例失访。
- 成本效益以增量净货币效益(INMB)计算,基于质量调整生命年(QALY)改善,采用社会视角(主要)和医疗系统视角(次要),使用非参数自举法评估不确定性并进行单因素敏感性分析。
主要发现
- 社会视角下,APM组与安慰剂手术组相比,2年随访成本高€971(95%CI -2013至4017),QALY改善0.015(95%CI -0.011至0.041),两者差异均未达统计学显著(95%CI宽且跨越无差异线)。
- 使用常规支付意愿阈值€35,000/QALY,APM的增量净货币效益为€-460(95%CI -3757至2698)。
- APM仅在支付意愿阈值升至约€65,000/QALY时才产生正的增量净货币效益,宽95%CI提示无论选择何种支付意愿阈值成本效益均不确定。
关键数值与推荐
- 退行性内侧半月板撕裂且根据美国风湿病学会临床标准无膝关节骨关节炎的35至65岁成人。
- APM组平均年龄52±7岁,男性60%(42/70);安慰剂手术组平均年龄52±7岁,男性62%(47/76)。
- 成本效益判定:增量净货币效益为正值才可认为APM具有成本效益。
- 支付意愿阈值€35,000/QALY下增量净货币效益为€-460(95%CI -3757至2698),阈值升至约€65,000/QALY时增量净货币效益转为正值。
临床怎么用
- 原文结论指出研究结果进一步支持临床实践指南不推荐对退行性半月板撕裂患者使用APM。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In patients with a degenerative tear of the medial meniscus, recent meta-analyses and systematic reviews have shown no treatment benefit of arthroscopic partial meniscectomy (APM) over conservative treatment or placebo surgery. Yet, advocates of APM still argue that APM is cost effective. Giving advocates of APM their due, we note that there is evidence from the treatment of other musculoskeletal complaints to suggest that a treatment may prove cost effective even in the absence of improvements in efficacy outcomes, as it may lead to other benefits, such as diminished productivity loss and reduced costs, and so the question of cost effectiveness needs to be answered for APM. QUESTIONS/PURPOSES: (1) Does APM result in lower postoperative costs compared with placebo surgery? (2) Is APM cost-effective compared with placebo surgery? METHODS: One hundred forty-six adults aged 35 to 65 years with knee symptoms consistent with a degenerative medial meniscus tear and no knee osteoarthritis according to the American College of Rheumatology clinical criteria were randomized to APM (n = 70) or placebo surgery (n = 76). In the APM and placebo surgery groups, mean age was 52 ± 7 years and 52 ± 7 years, and 60% (42 of 70) and 62% (47 of 76) of participants were men, respectively. There were no between-group differences in baseline characteristics. In both groups, a standard diagnostic arthroscopy was first performed. Thereafter, in the APM group, the torn meniscus was trimmed to solid meniscus tissue, whereas in the placebo surgery group, APM was carefully mimicked but no resection of meniscal tissue was performed; as such, surgical costs were the same in both arms and were not included in the analyses. All patients received identical postoperative care including a graduated home-based exercise program. At the 2-year follow-up, two patients were lost to follow-up, both in the placebo surgery group. Cost effectiveness over the 2-year trial period was computed as incremental net monetary benefit (INMB) for improvements in quality-adjusted life years (QALY), using both the societal (primary) and healthcare system (secondary) perspectives. To be able to consider APM cost effective, the CEA analysis should yield a positive INMB value. Nonparametric bootstrapping was used to assess uncertainty. Several one-way sensitivity analyses were also performed. RESULTS: APM did not deliver lower postoperative costs, nor did it convincingly improve quality of life scores when compared with placebo surgery. From a societal perspective, APM was associated with € 971 (95% CI -2013 to 4017) higher costs and 0.015 (95% CI -0.011 to 0.041) improved QALYs over 2-year follow-up compared with placebo surgery. Both differences were statistically inconclusive (a wide 95% CI that crossed the line of no difference). Using the conventional willingness to pay (WTP) threshold of € 35,000 per QALY, APM resulted in a negative INMB of € -460 (95% CI -3757 to 2698). In our analysis, APM would result in a positive INMB only when the WTP threshold rises to about € 65,000 per QALY. The wide 95% CIs suggests uncertain cost effectiveness irrespective of chosen WTP threshold. CONCLUSION: The results of this study lend further support to clinical practice guidelines recommending against the use of APM in patients with a degenerative meniscus tear. Given the robustness of existing evidence demonstrating no benefit or cost effectiveness of APM over nonsurgical treatment or placebo surgery, future research is unlikely to alter this conclusion.Level of Evidence Level III, economic analysis.
引用
- Kalske R, Kiadaliri A, Sihvonen R, et al. Arthroscopic Partial Meniscectomy for a Degenerative Meniscus Tear Is Not Cost Effective Compared With Placebo Surgery: An Economic Evaluation Based on the FIDELITY Trial Data. Clin Orthop Relat Res. 2024. PMID: 38905520. doi:10.1097/CORR.0000000000003094
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。